To evaluate ras-mediated signal transduction, an alkaline phosphatase gene (SEAP) was placed under the control of the ras-inducible phorbol ester response element (TRE) in murine fibroblasts (TRE-SEAP cells). The Kirsten ras gene was placed under the control of the glucocorticoid-inducible mouse mammary tumor virus promoter and introduced into the TRE-SEAP cells. Dexamethasone increased ras expression in the TRE-SEAP cells carrying the Kirsten ras gene and stimulated SEAP activity 25-fold. Lovastatin blocked dexamethasone induction of SEAP activity (50% inhibitory concentration, 0.5 ,LM) but did not affect phorbol ester-induced SEAP activity in the same cells. Lovastatin also did not block forskolin induction of SEAP activity in cells expressing SEAP under the control of the cyclic AMP response element.
Mutant ras genes are believed to contribute to carcinogenesis by distorting the normal signal transduction pathway that controls cell proliferation (4, 7, 11) . Inhibitors of rasmediated signal transduction may therefore be useful as antiproliferative agents. Recently, metabolic inhibitors of the mevalonate-biosynthetic pathway were found to block some of the biological effects of ras and were suggested as anti-Ras drugs (12, 23) . Lovastatin, an inhibitor of hydroxymethylglutaryl coenzyme A reductase, blocks processing of the ras precursor protein to its mature form and inhibits mammalian cell growth in vitro (8, 19, 23) . However, it is unclear whether lovastatin's growth-inhibitory activity is due to its interference with the posttranslational processing of ras proteins or to inhibition of other biochemical reactions that depend on normal levels of mevalonate or one of the metabolic products derived from mevalonate (6, 12) .
One of the biological properties expected of an anti-Ras drug is the ability to interfere with the signal transduction events stimulated by oncogenic ras genes. To examine the capacity of lovastatin to inhibit ras-stimulated signal transduction, an alkaline phosphatase reporter gene (SEAP) (2) was placed under the transcriptional control of the phorbol ester response element (TRE). The TRE was previously shown to be activated by an oncogenic form of ras (15, 22, 27) . Control plasmids containing the same reporter gene under the transcriptional control of the cyclic AMP response element (CRE) (21, 3) were also constructed. These plasmids were introduced into NIH 3T3 cells, and permanent cell lines were isolated. The resulting cell lines were examined for stimulation of SEAP activity in response to increased expression of a viral ras gene or biochemical stimulation of the phorbol ester and cyclic AMP response elements.
Synthetic oligonucleotides representing multimerized versions of the 12-0-tetradecanoylphorbol-13-acetate (TPA) or cyclic AMP response element (1, 10) were cloned into a mammalian reporter gene plasmid as shown in Fig. 1 (13) . Multiple isolates of the resulting MMTVras/TRE-SEAP and MMTV-ras/CRE-SEAP cell lines were obtained by selection of hygromycin-resistant colonies. The MMTV-ras/TRE-SEAP cell lines were screened for the ability to upregulate Kirsten ras transcription following exposure to dexamethasone (1.0 ,uM). Figure 2 shows the effect of dexamethasone treatment on Kirsten ras mRNA levels in MMTV-ras/TRE-SEAP cl-38 cells. As expected, Kirsten ras-specific mRNA levels increased approximately fivefold following exposure to dexamethasone for 24 h ( Fig.  2A) . SEAP-specific mRNA levels also increased significantly in the MMTV-ras/TRE-SEAP cells treated with dexamethasone ( the levels of alkaline phosphatase activity produced by several cell lines exposed to a specific series of inducing agents. Multiple clones of the MMTV-ras/TRE-SEAP and control cell lines were examined. Most of the MMTV-ras/ TRE-SEAP cell lines exhibited 5-to 30-fold stimulation of SEAP activity when exposed to appropriate inducing agents.
Clone 38 (cl-38) was selected for further analysis because it consistently exhibited increased expression of ras mRNA and reproducible increases in SEAP activity when treated with dexamethasone. As shown in Table 1 , dexamethasone increased SEAP activity in MMTV-ras/TRE-SEAP cl-38 cells and in a control cell line containing the MMTV promoter placed immediately in front of the SEAP gene (MMTV-SEAP cells). As expected, dexamethasone had no effect on SEAP activity in MMTV-ras/CRE-SEAP or TRE- (17, 24) .
The ability of lovastatin to inhibit stimulation of SEAP gene expression was tested in each of these cell lines. As shown in Table 2 , lovastatin blocked dexamethasone-stimulated SEAP activity in the MMTV-ras/TRE-SEAP cells, with a 50% inhibitory concentration (IC50) of approximately 0.5 ,uM. In the same studies, 5.0 ,uM lovastatin had little or no effect on dexamethasone, forskolin-IBMX-, and TPAstimulated SEAP activity in the MMTV-SEAP, MMTV-rasl CRE-SEAP, and TRE-SEAP cells, respectively. These studies indicate that 0.5 puM lovastatin selectively inhibits the signal transduction pathway that links ras gene expression with activation of the TRE in mammalian cells. Lovastatin also inhibited the ability of MMTV-ras/TRE-SEAP cells to form colonies in soft agar culture (75% inhibition at 0.5 ,uM, 100% inhibition at 5.0 ,uM).
The most likely explanation for lovastatin's interference with ras-stimulated signal transduction is drug-induced inhibition of the posttranslational modifications of ras that are required to produce biologically active mature Ras protein (14) . These modifications include a Ras-specific isoprenyl transferase reaction which has been shown to be sensitive to inhibitors of the mevalonate-biosynthetic pathway, such as lovastatin (5, 18) . Lovastatin blocks hydroxymethylglutaryl coenzyme A reductase activity, thereby inhibiting formation of mevalonate. Mevalonate serves as a precursor in the synthesis of a variety of isoprenoids, including farnesyl pyrophosphate. Several mammalian cell proteins in addition to Ras require isoprenylation, including lamin B (9) and low-molecular-mass GTP-binding proteins (20) . It is unclear whether lovastatin's antiproliferative activity is due to its interference with the posttranslational modification of Ras or one of these other mammalian cell proteins that normally undergo isoprenylation. However, the current study demonstrates that lovastatin is capable of inhibiting at least one of the transcriptional events normally stimulated by ras. This inhibition occurred at drug concentrations previously shown to be effective at blocking the isoprenylation of Ras in mammalian cells (25) . The Ras proteins in MMTV-ras/TRE-SEAP cl-38 cells were also examined by immunoprecipitation and gel electrophoresis following exposure to lovastatin (Fig. 3) . As expected, the amount of Ras protein in the membrane fraction decreased while that in the cytoplasmic fraction increased with increasing concentrations of lovastatin (Fig. 3A) . Simultaneous with this shift in the subcellular distribution of Ras, a slower migrating species of Ras protein, which is likely to be the Ras precursor protein, became more abundant in the cytoplasmic fractions (Fig. 3B) . It should be noted that the inhibition of ras-stimulated signal transduction observed in our studies occurred at concentrations of lovastatin that did not affect the other signal transduction pathways examined. These results suggest that suppression of ras activity by inhibitors of posttranslational Ras processing reactions may be an effective means of selectively inhibiting ras-stimulated transcriptional events.
